![]() |
Name |
Talafun
|
Molecular Formula | C13H12O8 | |
IUPAC Name* |
3-(2,5-dihydroxy-4-methoxybenzoyl)-4-methoxy-4-oxobut-2-enoicacid
|
|
SMILES |
COC(=O)C(=CC(=O)O)C(=O)c1cc(O)c(OC)cc1O
|
|
InChI |
InChI=1S/C13H12O8/c1-20-10-5-8(14)6(3-9(10)15)12(18)7(4-11(16)17)13(19)21-2/h3-5,14-15H,1-2H3,(H,16,17)/b7-4-
|
|
InChIKey |
DYBPDCNHCRZZTJ-DAXSKMNVSA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 296.23 | ALogp: | 0.5 |
HBD: | 3 | HBA: | 7 |
Rotatable Bonds: | 5 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 130.4 | Aromatic Rings: | 1 |
Heavy Atoms: | 21 | QED Weighted: | 0.182 |
Caco-2 Permeability: | -5.284 | MDCK Permeability: | 0.00001400 |
Pgp-inhibitor: | 0.001 | Pgp-substrate: | 0.002 |
Human Intestinal Absorption (HIA): | 0.86 | 20% Bioavailability (F20%): | 0.881 |
30% Bioavailability (F30%): | 0.977 |
Blood-Brain-Barrier Penetration (BBB): | 0.143 | Plasma Protein Binding (PPB): | 85.60% |
Volume Distribution (VD): | 0.355 | Fu: | 10.26% |
CYP1A2-inhibitor: | 0.279 | CYP1A2-substrate: | 0.521 |
CYP2C19-inhibitor: | 0.036 | CYP2C19-substrate: | 0.048 |
CYP2C9-inhibitor: | 0.451 | CYP2C9-substrate: | 0.317 |
CYP2D6-inhibitor: | 0.092 | CYP2D6-substrate: | 0.136 |
CYP3A4-inhibitor: | 0.025 | CYP3A4-substrate: | 0.089 |
Clearance (CL): | 4.421 | Half-life (T1/2): | 0.944 |
hERG Blockers: | 0.009 | Human Hepatotoxicity (H-HT): | 0.66 |
Drug-inuced Liver Injury (DILI): | 0.973 | AMES Toxicity: | 0.612 |
Rat Oral Acute Toxicity: | 0.133 | Maximum Recommended Daily Dose: | 0.078 |
Skin Sensitization: | 0.304 | Carcinogencity: | 0.036 |
Eye Corrosion: | 0.005 | Eye Irritation: | 0.604 |
Respiratory Toxicity: | 0.348 |